| Together, our workstation and biochips eliminate messy lab work as the biochips contain all the necessary ingredients to run multiplex assays. That automation eliminates manual labor in the lab, expedites the testing process, and improves the accuracy of results.
As new markers continue to be discovered in an effort to redefine the drug development process, the AVANTRA™Q400 biomarker workstation will be a valuable tool to enable validation of biomarkers in preclinical trials as well as provide a direct transition into clinical trials.
AVANTRA™Q400 biomarker workstation
Decision Biomarker’s technology provides precision multiplex assays, enabling evaluation of biomarker panels with a high level of accuracy. The AVANTRA™Q400 biomarker workstation is the only commercially available fully automated multiplex immunoassay system for proteins that can transition directly from preclinical to clinical trials testing, using the same platform while providing the same levels of performance. This will translate to more effective clinical trials and earlier, more cost effective decision making.
|
